Less Alzheimer's pathology with angiotensin receptor blocker use

September 12, 2012
Less alzheimer's pathology with angiotensin receptor blocker use
In autopsy findings, patients treated with angiotensin receptor blockers show less Alzheimer's disease-related pathology, according to a study published online Sept. 10 in the Archives of Neurology.

(HealthDay)—In autopsy findings, patients treated with angiotensin receptor blockers (ARBs) show less Alzheimer's disease (AD)-related pathology, according to a study published online Sept. 10 in the Archives of Neurology.

Ihab Hajjar, M.D., from the University of Southern California in Los Angeles, and colleagues evaluated the impact of ARB treatment on the neuropathy of AD using data from autopsy samples from 890 patients with hypertension (mean age at death, 81 years). markers, neuritic plaque, and neurofibrillary tangle measures were compared for those taking ARBs and those treated with other antihypertensive medications and untreated individuals.

The researchers found that participants treated with ARBs, with or without AD, showed significantly fewer amyloid deposition markers than those treated with other antihypertensive medications (lower Consortium to Establish a Registry of Alzheimer Disease score: odds ratio, 0.47; Alzheimer Disease and Related Disorders Association score: odds ratio, 0.43; Braak and Braak stage: odds ratio, 0.52; neuritic plaques: odds ratio, 0.59). Compared with untreated hypertensive patients, patients treated with ARBs also had less AD-related pathology. Participants who received ARBs had more frequent pathologic evidence of large vessel and , as they were more likely to have had a stroke.

"This autopsy study suggests that treatment with ARBs is associated with less amyloid accumulation and AD-related pathology independent of other AD risk factors," the authors write. "To our knowledge, it is the first human evidence to suggest that treatment with ARBs may have a selective beneficial effect on amyloid metabolism."

Explore further: Pulse pressure elevation could presage cerebrovascular disease in Alzheimer's patients

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Recommended for you

Plant reveals anti-Alzheimer's compounds

June 20, 2017

Japanese scientists have developed a method to isolate and identify active compounds in plant medicines, which accurately accounts for drug behavior in the body. Using the technique, they have identified several active compounds ...

Rate of Alzheimer's deaths on the rise

June 15, 2017

The rate of death from Alzheimer's disease in the United States increased by more than 50 percent in the past 15 years, according to new data from the Centers for Disease Control and Prevention.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.